^
    over6years
    Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=17, Completed, Bristol-Myers Squibb | N=120 --> 17
    Clinical • Enrollment change • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • BMS-908662